Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2...Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2019 to June 2020 were selected and divided into two groups.The experimental group was treated with Fengshi Qutong capsules combined with diclofenac sodium,and the control group was treated with sulfasalazine enteric-coated tablets.Results:The treatment efficacy,VAS score,BASDAI score,BASFI score,CRP level,TNF-α level,IL-Iβ level,and the incidence of adverse reactions between the two groups were significantly different(P<0.05).Conclusion:The application of Fengshi Qutong capsules combined with diclofenac sodium in the treatment of patients with ankylosing spondylitis is beneficial to improve the treatment efficacy,reduce the levels of CRP,TNF-α,and IL-Iβ,reduce the incidence of adverse reactions,and reduce the VAS,BASDAI and BASFI scores,rendering it of important clinical value.展开更多
The pharmacokinetics of a sustained- release formulation and an enteric- coated tablet of diclofenac sodium were studied on 8 healthy male volunteers in an open,randomized crossover study.Drug level in serum was assay...The pharmacokinetics of a sustained- release formulation and an enteric- coated tablet of diclofenac sodium were studied on 8 healthy male volunteers in an open,randomized crossover study.Drug level in serum was assayed by HPLC method.The changes in serum concentration were conformed to a l-compartment open model.The t_1/2 (Ke)averaged 2.15±0.17 and ll.60 ± l.95 h,and the areas under the drug concentration curves were 5.87 ± 0.67 and 5.55 ± 0.57μgh/ml for enteric-coated and sustained-release tablet of diclofenac sodium,respectively. The mean relative bioavailability of sustained-release tablet was 0.95 to that of enteric-coated tablet.展开更多
文摘Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2019 to June 2020 were selected and divided into two groups.The experimental group was treated with Fengshi Qutong capsules combined with diclofenac sodium,and the control group was treated with sulfasalazine enteric-coated tablets.Results:The treatment efficacy,VAS score,BASDAI score,BASFI score,CRP level,TNF-α level,IL-Iβ level,and the incidence of adverse reactions between the two groups were significantly different(P<0.05).Conclusion:The application of Fengshi Qutong capsules combined with diclofenac sodium in the treatment of patients with ankylosing spondylitis is beneficial to improve the treatment efficacy,reduce the levels of CRP,TNF-α,and IL-Iβ,reduce the incidence of adverse reactions,and reduce the VAS,BASDAI and BASFI scores,rendering it of important clinical value.
文摘The pharmacokinetics of a sustained- release formulation and an enteric- coated tablet of diclofenac sodium were studied on 8 healthy male volunteers in an open,randomized crossover study.Drug level in serum was assayed by HPLC method.The changes in serum concentration were conformed to a l-compartment open model.The t_1/2 (Ke)averaged 2.15±0.17 and ll.60 ± l.95 h,and the areas under the drug concentration curves were 5.87 ± 0.67 and 5.55 ± 0.57μgh/ml for enteric-coated and sustained-release tablet of diclofenac sodium,respectively. The mean relative bioavailability of sustained-release tablet was 0.95 to that of enteric-coated tablet.
